clinical-pathology-epidemiology-2019-keynote

2 / 6

Journal of Infectious Diseases and Treatment
ISSN: 2472-1093 Clinical Pathology & Epidemiology 2019 Page 24
Clinical Pathology and Epidemiology
February 27-28, 2019 | Prague, Czech Republic
7th Euroscicon Conference on
In recent years, many discoveries have profoundly changed our knowledge
on the relationships between bacteria and our cells, whether they are
immuno-competent cells or other somatic cells that are subject to bacterial
attack. We now better know how our cells detect bacterial aggressors using
receptors of restricted specificity belonging to innate immunity and able to
identify specific molecular patterns located on bacterial membranes, being
Gram-positive or negative germs or mycobacteria. Once this identification
has been carried out, a whole arsenal of inflammatory reactions is triggered
in order to destroy as quickly as possible bacterial germs in their aggression
phase. Faced with these defensive strategies deployed by the innate
immune system, bacteria do not remain inactive and in turn implement a
set of molecular reactions, including the mighty system of injectisomes,
to elude the immune responses aiming at their neutralization or even their
final destruction. What if, for a therapeutic purpose, we could counteract the
strategies implemented by bacteria to beat them at their own game? This is
what the Bio Immune(G)eneMedicine-in short BI(G)MED- is attempting to do
quite successfully by using ultra-low doses of molecules and relying on the
general principle of Hormesis. A short description of the method and some
clinical examples will help to better understand the merits of this sub-lingual
nanotherapy, which is moreover devoid of any undesirable side effects.
Bio Immune (G)ene MEDicine-BI(G)
MED-can neutralize bacterial
agents by beating them at their
own game
Gilbert Glady
European Bio Immune(G)ene Medicine Association, France
Biography
Gilbert Glady has graduate from Med School in
1977 and has completed his MD at the age of 27
years from Strasbourg University of medicine and
postdoctoral studies from Besancon and Paris-Nord
universities of medicine and was then an Intern in
Onco-Hematology in the university clinic for several
years. After a specialization in homeopathy and
naturopathy in Paris, he returned to the Alsace region
to work as a Private Practitioner. Through his work
and encounters, he developed interest and expertise
in Immunology and Immunogenetics that leaded
him to nanomedicine and nanobiotechnology. He
thus became in 2010, the Creator of the BI(G)MED
method (Bio Immune (G)ene Medicine) and Director
of EBMA, the European association responsible for
communication and trainings in the field of BI(G)
MED. He has participated in numerous international
congresses in immuno-allergology, infectiology and
oncology with posters and oral presentations and is
the Author of several publications on nanobiotherapy
in different journals.
Gilbert Glady, J Infec Dis Treat 2019, Volume: 5
DOI: 10.21767/2472-1093-C1-007